Sector News

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

July 16, 2015
Life sciences
Shire’s $54 billion tie-up with AbbVie–and the subsequent cancellation of that deal–shook up employees and stalled CEO Flemming Ornskov’s plans to transform the company into a biotech the likes of giants Gilead, Biogen and Celgene. It also took the Dublin drugmaker off course in one of its other endeavors: Dealmaking.
 
As Ornskov told The Wall Street Journal, his company is now playing catch-up to secure the deals that will help it on its way to Big Biotech status.
 
“We did lose 6 months,” he said.
 
Last summer, AbbVie–looking to lessen its reliance on best-seller and biosimilar target Humira–agreed to snatch up Shire at a price the Irish pharma couldn’t refuse. But it wasn’t long before new, stricter rules on U.S. tax inversions scared the Illinois drugmaker off, bringing the deal crashing down.
 
For Shire, though, the setback was real. It lost out on one of its targets while the AbbVie takeover plans were occupying its time, and rivals upped the prices on the kinds of biotechs Ornskov had his eye on, the WSJ reports.
 
The result? Shire is now casting a wider net for pickup targets, the Journal notes. Yes, it’s still focused on rare diseases, building up the business it strengthened with 2013’s agreement to buy ViroPharma. But it’s also looking at companies working on maladies that share things in common with rare diseases–a limited number of patients treated at specialized centers, for example.
 
For now, Ornskov says he’s interested in adding meds and companies that work on diseases of the brain, stomach, eyes, hormones and metabolism. Any buys would follow this year’s deal for NPS Pharma, a GI specialist that Ornskov started pressing employees to snag within days of the AbbVie deal collapse, Shire business development head Mark Enyedy told the paper.
 
And they’re likely to happen quickly. “From the AbbVie situation, I understand that one opportunity cost is time,” Ornskov said. “The longer something takes, the longer you wait, the greater the likelihood that you may not get it done.”
 
By Carly Helfand
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).